Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Askel Healthcare to raise 5 million euros for clinical research of its COPLA® - implant to treat knee pain caused by cartilage damage


News provided by

Askel Healthcare Oy

16 May, 2023, 06:16 GMT

Share this article

Share toX

Share this article

Share toX

HELSINKI, May 16, 2023 /PRNewswire/ -- Askel Healthcare, the Finnish medical technology company offering a new method for the treatment of knee cartilage damage, has started a fundraising campaign to raise up to 5 million euros to finance clinical trials of its COPLA® implant. The public phase of the ongoing fundraising campaign started today and closes on 18 June 2023. An investor meeting will take place on 24 May 2023 at 16:00 EEST at VALO Hotel & Work and online.

Askel Healthcare's COPLA® implant is a new biodegradable implant for the surgical treatment of cartilage damage in the knee. Askel Healthcare is targeting the global cartilage repair market with the COPLA® implant which is estimated to be up to 3 billion USD. The company aims to become the global standard of surgical knee cartilage repair.

Key highlights of the share issue:

-  The company is offering 7.56-21.42% of equity for EUR 8.10 per share with a minimum investment of 50 shares. Shares are offered globally through brokers Invesdor GmbH and Oneplanetcrowd B.V. Additional details are available on the campaign website at https://www.invesdor.com/rounds/f589c08e-3245-4ad9-ba03-96c3277b0c43#/.

-  The subscription period is 16 May-18 June 2023.

-  Askel Healthcare's mission is to keep people in motion through its universal COPLA® implant, a ground-breaking innovation for repair of knee cartilage damage. It is easy to implant and enables fast recovery to pain-free activity. The implant is a result of more than ten years of orthopedic and tissue engineering research at the University of Helsinki and Tampere University in Finland.  

-  The company is currently in the clinical investigation phase. Its primary goal is market authorization for the COPLA® implant and product launch in the US by 2028.

-  Key investment highlights:

(i)  The global knee cartilage repair market is estimated to be up to 3 billion USD;

(ii)  Knee cartilage does not have the capacity to heal on its own, and untreated knee cartilage damage is one of the main reasons for developing osteoarthritis. So far, there is lack of reliable and accessible treatment options for knee cartilage repair. The long-term results of the most common treatment method currently available, microfracture, are insufficient, and new methods that have entered the market are expensive;

(iii)  The company's own cost-effective and scalable in-house production and moderate supply chain costs enable an effective global business model;

(iv)  Askel Healthcare has an extensive global network of top experts and key opinion leaders in knee cartilage repair.

-  Key advantages of the COPLA® implant:

(i)  Fast recovery through full weight-bearing on the operated leg immediately after surgery;

(ii)  Affordability; surgical simplicity; universal.

(iii)  Long-term clinical results as a result of good repair tissue quality driven by timely mechanical loading of the repaired tissue site.

-  Key use of funds:

(i)  Demonstration of safety of the COPLA® implant;

(ii)  Authority approval for the main clinical trial aiming for market authorization;

(iii)  Strengthening the Intellectual Property Rights (IPR).

A more detailed description of the share issue is presented in the Information Memorandum here https://www.invesdor.com/rounds/f589c08e-3245-4ad9-ba03-96c3277b0c43#/.

"Askel Healthcare is on a major mission: keeping people in motion. Knee pain is extremely disabling and the number one factor preventing people from doing physical activities they love. To solve this universal problem, we have developed the COPLA® implant. It works together with the biological environment of the knee, allowing the joint surface to repair itself. It is the only cartilage repair method that allows the patient to place full body weight on the operated leg immediately after the surgery. This shortens the recovery time and enables patients to return to their daily activities faster. Moreover, the mechanical stimuli resulting from physical activity is paramount for cartilage tissue to rebuild itself and thus for long-term clinical effects. Together with our world-class network of clinicians, we aim to be the global standard in surgical knee cartilage repair," said Virpi Muhonen, CEO of Askel Healthcare Ltd.

"Developing health technology requires money and patient investors. Crowdfunding is a vital source of equity funding for MedTech companies like Askel Healthcare, as venture capital investors in this field are almost non-existent in Finland. Investors on the Invesdor platform have shown interest in healthcare companies in recent years, as these have significant return potential when everything goes right," comments Mari Lymysalo, Managing Director of Invesdor Oy.

Invitation to investor event on 24 May 2023 at 4:00 p.m. EEST

Askel Healthcare invites investors, analysts and media to an investor event on 24 May 2023 at 4:00 p.m. EEST, where the company management will present the company, its strategy and the ongoing share issue, and answer questions from the audience. The hybrid event will be held in English at VALO Hotel & Work at Mannerheimintie 109, 00280 Helsinki. Participants can also join the event online.

To register for the event, please send an e-mail to niklas.green@invesdor.com. After successful registration, a link to the online event will be sent to online participants who have registered in advance for the event. The event materials will be sent to registered participants after the event. For additional information, please contact Askel Healthcare CEO, Virpi Muhonen at v.muhonen@askelhealthcare.com.

Additional information:

Askel Healthcare, CEO Virpi Muhonen. Tel. +358 40 489 3840

Invesdor Finland, CEO Mari Lymysalo. Tel. +358 40 356 6160

About Askel Healthcare

Askel Healthcare is a Finnish medical technology company set to transform surgical knee cartilage treatment and recovery. Our mission is to keep people in motion through our universal COPLA® implant, which is a ground-breaking innovation for the repair of knee cartilage defects. For more information, visit: www.askelhealthcare.com and https://youtu.be/RSZwLWwfwe8.

About Invesdor

Invesdor Group is among the largest European investment and financing platforms, with over €436 million in funding volume. It currently operates in Finland, Germany, Austria and the Netherlands. Invesdor's digital investment platform offers tailor-made financing solutions for unlisted companies. For more information, visit: https://www.invesdor.com.

The following files are available for download:

https://mb.cision.com/Main/22234/3769543/2060253.pdf

Press release (PDF)

https://news.cision.com/askel-healthcare-oy/i/founder,c3179054

Founder

Modal title

Also from this source

Askel Healthcare to Present First Clinical Trial Results of Its COPLA® Knee Cartilage Implant at the 9th Joint Preservation Congress in Warsaw, Poland on June 14-15, 2024

Askel Healthcare, a Finnish medical technology company pioneering the treatment and repair of focal knee cartilage defects, will present results from ...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Medical Equipment

Medical Equipment

Accounting News & Issues

Accounting News & Issues

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.